Japan Idiopathic Pulmonary Fibrosis Treatment Market to Grow at 7.74% During 2024-2032, Impelled by Increasing Geriatric Population

According to the latest report by IMARC Group, titled "Japan Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-term Care Facilities, and Others), and Region 2024-2032," the Japan idiopathic pulmonary fibrosis treatment market is expected to grow at a CAGR of 7.74% during 2024-2032. Idiopathic pulmonary fibrosis (IPF) refers to a medical condition that causes the lungs to become scarred, which leads to breathing difficulties. This condition is a serious lung disease, which causes the growth of scar tissues inside the lungs and slows the oxygen flow to the bloodstream, leading to a persistent dry cough, loss of appetite and weight, rounded and swollen fingertips and shortness of breath. Its diagnosis includes breathing and blood tests, chest X-ray and computed tomography (CT) scan, bronchoscopy and lung biopsy. The treatment for this condition involves oxygen therapy, pulmonary rehabilitation, lung transplant and anti-fibrotic drugs that aid in slowing lung damage and improving the quality of life.

Japan Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The market in Japan is primarily driven by the growing prevalence of idiopathic pulmonary fibrosis among the masses. Coupled with the increasing geriatric population, which is more prone to medical ailments, this is creating a positive market outlook. Along with this, the growing commercialization of novel drugs and the increasing awareness regarding IPF and its available treatments among individuals are providing a boost to the market growth. Moreover, the rising investments by key players in extensive research and development (R&D) activities to introduce new treatment approaches are impacting the market favorably across the country. Additionally, numerous initiatives undertaken by the government to promote and create awareness regarding IPF disease are significantly supporting the demand for IPF treatments among individuals. Other factors, including the growing number of clinical trials, continuous improvements in the healthcare infrastructure, the inflating disposable income levels of the masses and continual technological advancements in the healthcare sector, are also positively influencing the market across Japan.

Market Summary:

• On the basis of the drug class, the market has been segmented into MAPK, tyrosine and autotaxin inhibitors.
• Based on the end-user, the market has been segregated into hospitals, long-term care facilities and others.
• On the basis of the region, the market has been divided into Kanto, Kinki, Central/ Chubu, Kyushu-Okinawa, Tohoku, Chugoku, Hokkaido and Shikoku regions.
• The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
   

Report Scope:

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste 
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800